Andrew Emili
 | The topic of this article may not meet Wikitia's general notability guideline. |
Andrew Emili | |
|---|---|
| Add a Photo | |
| Alma mater | University of Toronto |
| Occupation | Professor of Oncological Sciences |
| Employer | Oregon Health and Science University |
| Website | emililab |
Dr. Andrew Emili is a professor in the department of Oncological Sciences at Oregon Health and Science University. He is cross appointed in the Department of Biomedical Engineering and the Department of Chemical Physiology and Biochemistry.[1]. Prior to joining OHSU, Emili was the Founding Director for the Center for Network Systems Biology and Data Science at Boston University[2].
Dr Emili is an internationally recognized leader in functional proteomics, systems biology and precision mass spectrometry and the development of innovative technologies to systematically map protein interaction networks, molecular pathways and macromolecular complexes in healthy and diseased cells and tissues on a proteome-scale. Dr. Emili directs a multidisciplinary team with a distinguished track record in systems biology, focusing on basic and translational studies relevant to cancer and other diseases. His group develops high-throughput methods for characterizing molecular associations of broad biomedical significance, publishing global ‘interactome’ maps of unprecedented quality, scope and resolution[3]
Early Life and Education
Dr. Emili received his PhD in Molecular and Medical Genetics from the University of Toronto in 1997. From 1997 to 2000, he pursued post-doctoral studies as a Damon Runyon/Walter Winchell Cancer Research Fellow with the Nobel laureate Leland H. Hartwell at the Fred Hutchison Cancer Research Center in Seattle, while learning protein mass spectrometry with Prof. John Yates III at the University of Washington.
Research and Career
Since establishing his own independent research laboratory in 2000, Dr. Emili has developed and applied innovative functional proteomics, functional genomics and bioinformatics methods to investigate biological systems and molecular association networks in human cells and model organisms. His lab develops and uses precision mass spectrometry-based techniques to characterize protein networks in tumor cells and other disease systems in a comprehensive, quantitative, high-throughput manner. His group aims for breakthrough insights into the composition and mechanistic role of macromolecules in diverse cells and tissues, with the long-term goal of translating this knowledge into new diagnostics and therapeutics. Dr. Emili has mentored numerous trainees who have gone on to leadership positions in academia, industry and medicine. By working with renowned biology, clinical and industry partners, his trainees generate biological ‘connectivity’ diagrams of unprecedented quality, scope and utility. By charting new directions in systems biology, his group pushes the boundaries in network biology via the creation of high-impact papers, resources and tools.
Over a span of 20 years, Dr. Emili has had a significant impact in the field of scientific research. He has authored 270 peer-reviewed papers that have been cited over 38,000 times, achieving an h-index of 87[4]. His work includes extensive genome-wide studies of protein complexes in yeast, E. coli, and humans, revealing many associations relevant to fundamental biological systems and disease outcomes. Dr. Emili is also highly engaged in the scientific community. He reviews for prestigious journals, participates in NIH study sections and various national and international review panels, and his research data is frequently accessed through public databases. Additionally, he has contributed to the field of network and systems biology through his editorial work on books that have been downloaded over 60,000 times. Dr. Emili is also a prominent speaker, having delivered more than 200 talks at various national and international conferences, symposia, and workshops.
Patents
- Emili, A – “Protein sequencing method and reagents” US Patent #10481162, Issued 11/19/2019[5]
- Emili, A – “PROTEIN SEQUENCING METHODS AND REAGENTS” USPTO Publication #:20180299460, Approved Nov 2021, Issuance Pending
- Emili, A – Protein sequencing method and reagents; Patent #9566335, Issued February 14, 2017[6]
- Emili, A – “Method for Identification of Macromolecule Targets of Analytes,” USPTO Patent #8192999, Issued 06/05/2012[7]
- Aaron Beeler, Andrew Emili - “NEW GENERATION PROTEIN SEQUENCING REAGENTS” US Patent Submission
- Emili, A – Use of SFRP-3 in the assessment of heart failure, USPTO Patent #8691587, Issued Apr. 8, 2014[8]
- Emili, A – Use of IGFBP-7 in the assessment of heart failure, USPTO Patent #10488422, Issued Nov. 26, 2019[9]
- Emili, A – Automatic sample loader for use with a mass spectrometer, US Patent Office (USPTO) Patent #7109477, Issued September 19, 2006[10]
- Roche Diagnostics Gmbh/F. Hoffmann-La Roche AG “Use of a Panel of Biomarkers in the Assessment of Heart Failure” PCT/EP2008/000576, PCT/EP2008/001842 (9 other related submissions 2008-13).
Honors
- 1990: Summa Cum Laude, McGill University, QC Canada
- 1991: Graduate Fellowship, Medical Research Council, Canada
- 1997: Cancer Research Fellow, Damon Runyon Cancer Research Foundation, USA
- 2007: Subash Verma Research Award, Heart & Stroke/Lewar Centre Excellence, U. Toronto
References
- ↑ "Andrew Emili Ph.D. | OHSU People | OHSU".
- ↑ "Andrew Emili | Biology".
- ↑ Pourhaghighi, Reza; et al. (2020). "BraInMap Elucidates the Macromolecular Connectivity Landscape of Mammalian Brain" (PDF). Cell Systems. 10 (4): 333–350.e14. doi:10.1016/j.cels.2020.03.003. PMID 32325033.
- ↑ "Andrew Emili".
- ↑ US 10481162, issued 11/19/2019
- ↑ US 9566335, issued February 14, 2017
- ↑ US 8192999, issued 06/05/2012
- ↑ US 8691587, issued Apr. 8, 2014
- ↑ US 10488422, issued Nov. 26, 2019
- ↑ US 7109477, issued September 19, 2006
External links
This article "Andrew Emili" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.